---

(Fierce) - Gilead Sciences ($GILD) wants a bigger stake in the massive cancer drugs business, building on the Foster City, CA-based company's large footprint in anti-HIV and virology treatments. And today the major drugmaker announced a $510 million cash buyout of Canada's YM BioSciences ($YMI) in a deal that includes a lead JAK inhibitor candidate for combatting blood diseases.